Can Foundayo (Orforglipron) Cause Low Libido?

What Orforglipron (Foundayo) Is and How It Works

Orforglipron, sold under the brand name Foundayo, is an oral GLP-1 receptor agonist approved for weight management and type 2 diabetes. Unlike injectable GLP-1 medications such as semaglutide, orforglipron is taken as a once-daily pill, making it a more convenient option for many patients and a meaningful advancement in this class of therapy.

The drug works by mimicking the body's natural GLP-1 hormone. This action suppresses appetite, slows gastric emptying, and improves blood sugar regulation. Because it targets the same receptor as injectable GLP-1 drugs, its benefits for weight loss and metabolic health are comparable, but its oral format means it is reaching a broader population of people who prefer not to use injections.

Because Foundayo was newly approved, researchers and clinicians are still building a full picture of its long-term effects, including how it may interact with hormones that influence sexual health.

Does Orforglipron List Low Libido as an Official Side Effect

As of the clinical trial data published through 2026, low libido does not appear as a listed side effect of orforglipron. The drug's documented side effect profile centers almost entirely on gastrointestinal symptoms. Nausea is the most commonly reported complaint, followed by vomiting, diarrhea, and constipation. These effects are consistent with what has been observed across the broader GLP-1 drug class.

That said, the absence of a listing is not the same as the absence of a risk. Because orforglipron is relatively new, long-term sexual health data is limited compared to older GLP-1 agents that have been studied in larger populations over more years. Patient-reported experiences, including changes in sex drive, often surface after broader real-world use rather than in controlled trials.

If you are noticing a change in libido while taking Foundayo, the experience is worth taking seriously even if it is not prominently flagged in the prescribing information.

Why Some People on GLP-1 Drugs Report Changes in Sex Drive

Several indirect mechanisms may explain why people on orforglipron or other GLP-1 medications notice shifts in sexual desire, even when low libido is not a direct drug effect.

Significant caloric restriction and rapid weight loss can lower both testosterone and estrogen levels. Both hormones play a central role in sexual desire for men and women. When the body enters a significant caloric deficit, it may reduce hormone production as part of a broader adaptive response.

Nausea and fatigue, common in the first several weeks of GLP-1 therapy, can independently suppress interest in sex. Feeling physically unwell has a predictable effect on desire, and this does not require any direct hormonal mechanism.

Psychological factors also come into play during weight loss. Body image shifts, mood changes, and the cognitive load of managing a new medication routine can affect sexual confidence and desire in both directions. Some people report increased confidence and improved desire as weight loss progresses, while others feel more self-conscious or emotionally drained during the adjustment period.

The Hormonal Connection Worth Understanding

GLP-1 receptor agonists have been associated with modest reductions in testosterone in some male patients, though researchers are still debating the exact mechanism. One possible pathway involves improved insulin sensitivity, which can raise levels of sex hormone-binding globulin (SHBG). When SHBG rises, it binds more testosterone, leaving less of the free testosterone available that the body actually uses.

In women, rapid fat loss can disrupt estrogen levels and, in some cases, menstrual cycles. Estrogen plays a meaningful role in vaginal lubrication, sensitivity, and overall sexual desire. Disruption in estrogen levels may therefore translate into changes in sexual experience and interest.

The table below summarizes the most commonly discussed GLP-1 side effects alongside their reported frequency and possible connection to libido.

When a Change in Sex Drive Deserves Medical Attention

Not every dip in libido requires an urgent clinical response, but some situations call for a closer look. Persistent low libido lasting more than four to six weeks after starting orforglipron or after a dose increase is worth raising with your provider. At that point, it is reasonable to ask whether the medication or another underlying factor is responsible.

A provider evaluating this concern should consider ruling out thyroid dysfunction, anemia, and depression. All three conditions can coexist with GLP-1 use and independently cause or worsen low libido. A hormone panel including free testosterone, estradiol, and TSH can help clarify whether hormonal shifts are contributing to the change you are experiencing.

Importantly, this conversation does not have to wait for an in-person appointment. Doctronic's free AI consultations, available 24/7 and HIPAA aligned, can help you organize your symptoms and determine which questions to bring to a clinical provider.

Practical Steps If Your Sex Drive Changes on Foundayo

If you notice a decrease in libido after starting orforglipron, there are several practical steps that may help before you make any decisions about your medication.

First, do not stop orforglipron without speaking to a provider. The weight management and metabolic benefits of this medication are significant, and a temporary side effect may not outweigh those gains. Stopping abruptly also removes the opportunity to understand whether the medication is truly the cause.

Timing matters. Libido disruption on GLP-1 therapy most often peaks during the nausea-heavy early weeks and tends to improve between weeks 8 and 12 as the body adapts to the drug. Tracking your symptoms with a simple journal can help you and your provider identify patterns.

Finally, consider a targeted lab workup. Asking for free testosterone, estradiol, TSH, and a complete blood count gives a clinician the data needed to determine whether the medication, rapid weight loss, or an unrelated condition is driving what you are experiencing. A proactive conversation is always easier than waiting for symptoms to worsen.

Frequently Asked Questions

Is low libido a documented side effect of orforglipron?

Low libido does not appear as a listed side effect in orforglipron clinical trial data published through 2025. The known side effect profile focuses on gastrointestinal symptoms. However, because Foundayo is newly approved, long-term sexual health data remains limited, and indirect mechanisms could still affect some patients.

How long does low libido from GLP-1 medications typically last?

For many people, libido disruption on GLP-1 therapy peaks during the early nausea and fatigue phase and tends to improve between weeks 8 and 12 as the body adjusts. If low libido persists beyond four to six weeks after starting or increasing your dose, it is worth discussing with a clinician to rule out other contributing factors.

Can losing weight on Foundayo actually improve sex drive over time?

Yes, for many people it can. Sustained weight loss often improves testosterone levels, reduces inflammation, and boosts body confidence, all of which may increase sexual desire over time. The early phase of treatment can feel disruptive, but longer-term metabolic improvements frequently have a positive effect on sexual health and overall wellbeing.

Should I stop taking orforglipron if my libido decreases?

Do not stop orforglipron without speaking to a provider first. The weight management and metabolic benefits may outweigh a temporary side effect. A clinician can help determine whether the change is medication-related, hormonal, or tied to another condition, and can suggest strategies to manage symptoms while continuing your treatment plan.

What lab tests should I ask for if I notice sexual side effects on orforglipron?

Ask your provider about a hormone panel that includes free testosterone, total testosterone, estradiol, and TSH to check thyroid function. A complete blood count can screen for anemia, and a depression screening may also be appropriate. These tests help clarify whether the medication or an unrelated condition is contributing to your symptoms.

The Bottom Line

Current clinical trial data does not list low libido as a direct side effect of orforglipron (Foundayo), but real biological pathways, including hormonal shifts from rapid weight loss, nausea-driven fatigue, and modest changes in sex hormone availability, make the experience plausible for some people. The good news is that most of these changes appear to be temporary, often resolving as the body adjusts to GLP-1 therapy. Doctronic, the first AI legally authorized to practice medicine and trusted for over 22 million AI consultations, offers free assessments and $39 video visits available 24/7 so you can get a personalized evaluation without a long wait. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.